Posted: 29 January 2026
4DMedical has secured more than US$100 million (approximately AU$150 million) in new institutional funding, with the capital having been raised to accelerate U.S. market expansion and strengthen its leadership in software-based lung imaging.
“This is an extraordinarily important and validating event for multiple reasons,” said Andreas Fouras, PhD, Founder and Chief Executive Officer of 4DMedical. “First, it reflects growing global recognition of the technological leadership of 4DMedical, including our groundbreaking products such as CT:VQ™. And it recognises both the commercial progress and even greater growth potential we have in the U.S.”
Backed by the new institutional funding, 4DMedical is advancing its respiratory imaging technology and expanding the U.S. rollout of its FDA-cleared CT:VQ™ software. CT:VQ™ is a software-as-a-service technology that provides ventilation and perfusion insights derived from CT imaging, delivering quantified and functional information not available through traditional imaging methods.
Within four months of receiving U.S. Food and Drug Administration clearance, CT:VQ™ was deployed by four U.S. academic medical centres: Stanford, Cleveland Clinic, University of Miami and UC San Diego Health. These early deployments reflect growing interest from clinicians seeking actionable lung function data to support diagnosis, treatment planning and longitudinal monitoring.
“With this strong institutional backing and a strengthened balance sheet, we will scale adoption, accelerate R&D, deepen partnerships, and dominate the global marketplace for software-based lung imaging tools,” Professor Fouras said.
The funding will be used to expand U.S. availability of CT:VQ™, support implementation at scale across hospitals and health systems, and provide customer training and technical support to integrate the technology into existing clinical workflows. Ongoing research and development, operational scale and flexibility to support sustained clinical partnerships have also been identified as priorities.
Following the raise, 4DMedical reported a pro forma cash position exceeding US$130+ million (AU$200+ million), supporting the company’s U.S. expansion strategy and growing installed base.
4DMedical Limited (ASX:4DX) is a global medical technology company that develops advanced software-based cardiothoracic imaging technology, integrating proprietary algorithms and artificial intelligence to deliver deep, quantitative insights from routine clinical imaging to support clinical decision-making in respiratory and cardiopulmonary care.
